Rochester, NY -- (SBWIRE) -- 12/03/2013 -- EnteroMedics (NASDAQ:ETRM) shares soared today hitting $2.05 for a price gain of 49% at the high. Traders bid up shares after the company reported new clinical trial data for its Maestro system, designed to treat obesity by blocking nerves with electrical impulses making patients feel less hungry and more satisfied.
EnteroMedics said patients on the Maestro RC system lost 25 percent of their excess weight, or 10 percent of their total body weight, after 18 months. Patients who received a fake implant lost only 4 percent of their total weight.
ETRM is running a five-year study of the system.
The system is approved in Europe and Australia, but not the U.S.
Enteromedics (NASDAQ:ETRM) will probably get a lot of attention over the next few days. The more traders paying attention to a stock the better the chance for volatility smart traders can profit from.
WhisperfromWallStreet has been teaching investors how to trade OTC stocks since 2005. We clearly explain the market dynamics behind most major moves in the OTC markets and provide readers with time tested, easy to follow strategies they can use to stay ahead of the pack.
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)